Compare COCH & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COCH | CNTX |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.7M | 51.5M |
| IPO Year | N/A | 2021 |
| Metric | COCH | CNTX |
|---|---|---|
| Price | $0.70 | $0.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.00 | ★ $6.60 |
| AVG Volume (30 Days) | 738.0K | ★ 5.0M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.55 |
| 52 Week High | $1.89 | $3.62 |
| Indicator | COCH | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.72 | 30.98 |
| Support Level | $0.64 | $0.55 |
| Resistance Level | $0.74 | $1.26 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 22.33 | 64.54 |
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.